| Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study H Kim, S Kim, S Han, PP Rane, KM Fox, Y Qian, HS Suh BMC public health 19, 1-11, 2019 | 134 | 2019 |
| Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US PP Rane, S Guha, S Chatterjee, RR Aparasu Research in Social and Administrative Pharmacy 13 (2), 358-363, 2017 | 76 | 2017 |
| Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea S Kim, S Han, PP Rane, Y Qian, Z Zhao, HS Suh PLoS One 15 (1), e0228472, 2020 | 31 | 2020 |
| A systematic review of direct cardiovascular event costs: an international perspective S Ryder, K Fox, P Rane, N Armstrong, CY Wei, S Deshpande, L Stirk, ... Pharmacoeconomics 37, 895-919, 2019 | 31 | 2019 |
| Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy SP Nagar, PP Rane, KM Fox, J Meyers, K Davis, A Beaubrun, H Inomata, ... Circulation Journal 82 (4), 1008-1016, 2018 | 27 | 2018 |
| Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review MB Betts, P Rane, E Bergrath, M Chitnis, MK Bhutani, C Gulea, Y Qian, ... Health and quality of life outcomes 18, 1-12, 2020 | 18 | 2020 |
| Treatment patterns of lipid‐lowering therapies and possible statin intolerance among statin users with clinical atherosclerotic cardiovascular disease (ASCVD) or diabetes … WJ Chen, YC Wen, KM Fox, LJ Shen, LY Lin, Y Qian, Z Zhao, PP Rane, ... Journal of Evaluation in Clinical Practice 26 (4), 1171-1180, 2020 | 9 | 2020 |
| Estimating years of life lost due to cardiovascular disease in Japan H Arai, K Mortaki, P Rane, C Quinn, Z Zhao, Y Qian Circulation Journal 83 (5), 1006-1010, 2019 | 9 | 2019 |
| Understanding the patient perception of statin experience: a qualitative study M Vrablik, AL Catapano, O Wiklund, Y Qian, P Rane, A Grove, ML Martin Advances in Therapy 36, 2723-2743, 2019 | 6 | 2019 |
| Characteristics of patients with dyslipidemia treated in routine care setting in China G Liu, J Shepherd, P Rane, Z Zhao, H Bailey, N Williams, Y Qian Journal of Drug Assessment 8 (1), 192-198, 2019 | 6 | 2019 |
| Utilization patterns of lipid-lowering therapies in patients with atherosclerotic cardiovascular disease or diabetes: a population-based study in South Korea S Kim, H Kim, E Kim, S Han, PP Rane, KM Fox, Z Zhao, Y Qian, HS Suh Clinical Therapeutics 40 (6), 940-951. e7, 2018 | 5 | 2018 |
| Patients' beliefs regarding counseling provided by community pharmacists: an application of the theory of planned behavior ML Fleming, EA Ferries, MD Hatfield, N Atreja, A Yucel, PP Rane, ... Journal of Pharmaceutical Health Services Research 6 (1), 77-79, 2015 | 5 | 2015 |
| Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: a systematic literature review RJ Motzer, PP Rane, TL Saretsky, D Pawar, AM Nguyen, M Sundaram, ... European Urology, 2023 | 4 | 2023 |
| The use of interquartile deviation in establishing delphi panel consensus: A prioritization of intravenous immunoglobulin utilization J Orange, B Lennert, P Rane, M Eaddy Value in Health 18 (7), A721, 2015 | 3 | 2015 |
| Proton Pump inhibitor prescribing trend in the us Ambulatory setting P Rane, RR Aparasu, S Guha Value in Health 18 (3), A265, 2015 | 3 | 2015 |
| Risk of pneumonia associated with proton pump inhibitor use among community dwelling adults with gastroesophageal reflux disease P Rane, S Guha, K Garey, H Chen, ML Johnson, RR Aparasu VALUE IN HEALTH 20 (5), A179-A180, 2017 | 1 | 2017 |
| Pembrolizumab plus lenvatinib vs nivolumab plus cabozantinib in patients with metastatic renal cell carcinoma: A matching adjusted indirect comparison (MAIC). P Rane, L Walton, M Schmidinger, A Peer, S Mt-Isa, JE Burgents, ... Journal of Clinical Oncology 42 (4_suppl), 399-399, 2024 | | 2024 |
| Pembrolizumab plus lenvatinib (P+ L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA). K Yan, P Rane, M Schmidinger, A Peer, E Druyts, JE Burgents, ... Journal of Clinical Oncology 42 (4_suppl), 422-422, 2024 | | 2024 |
| Pembrolizumab plus lenvatinib (P+ L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA). P Rane, K Yan, M Schmidinger, A Peer, E Druyts, JE Burgents, ... Journal of Clinical Oncology 42 (4_suppl), 421-421, 2024 | | 2024 |
| Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature MB Betts, P Rane, E Bergrath, M Chitnis, MK Bhutani, C Gulea, Y Qian, ... | | 2020 |
